Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Centrus Energy Corp (LEU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Centrus Energy Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Centrus Energy Corp trades at $166.17 (market cap $3.26B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| ACAD | LEU | |
|---|---|---|
Market Cap | $4.49B | $3.26B |
Sector | Health | Energy |
52-Week High | $28.06 | $436.00 |
52-Week Low | $20.06 | $146.61 |
Enterprise Value | $3.69B | $2.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Centrus Energy (LEU) trades at $174.23, up 7.46% today, with mixed technical signals showing neutral momentum. The company reported strong Q1 2026 earnings beat but faces valuation concerns with a P/E of 63.36. Recent catalysts include a $900 million DOE contract and inclusion in the S&P SmallCap 600 index, positioning LEU as the sole U.S.-licensed HALEU producer amid growing nuclear energy demand.
LEU offers exposure to U.S. nuclear fuel supply chain growth with $3.9 billion contracted backlog, but high valuation and execution risks warrant caution. Analyst consensus targets $219.50 (26% upside) with no sell ratings, though recent earnings misses and declining 2026 profit margins highlight operational challenges. The stock's premium valuation requires sustained contract execution and margin improvement to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
